Literature DB >> 301244

Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia.

C M Wilfert, R H Buckley, T Mohanakumar, J F Griffith, S L Katz, J K Whisnant, P A Eggleston, M Moore, E Treadwell, M N Oxman, F S Rosen.   

Abstract

We observed persistent ECHOvirus infection of the central nervous system, as defined by continued presence of isolatable virus in cerebrospinal fluid, in five patients with agammaglobulinemia. The immunologic deficit in each was characterized by absence of surface-immunoglobulin-bearing B lymphocytes and of lymph-node cortical follicles, but normal T-cell function. ECHOviruses 30, 19, 9 and 33 were recovered from cerebrospinal fluid for periods varying from two months to three years. The patients had few signs of acute central-nervous-system infection. Three of the five patients had a dermatomyositis-like syndrome, with peripheral lymphocytes that reacted with anti-human leukemia-specific primate and rabbit serums in a cytotoxicity assay. These data suggest that intact B-cell function is essential for eradication of ECHOvirus infection of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301244     DOI: 10.1056/NEJM197706302962601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  52 in total

Review 1.  Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.

Authors:  P P Sanna; D R Burton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 2.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 3.  Infection of immunosuppressed patients.

Authors:  H E Kay
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

4.  Discordant phenotype in siblings with X-linked agammaglobulinemia.

Authors:  M J Bykowsky; R N Haire; Y Ohta; H Tang; S S Sung; E S Veksler; J M Greene; S M Fu; G W Litman; K E Sullivan
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

Review 5.  Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.

Authors:  William T Shearer; Thomas A Fleisher; Rebecca H Buckley; Zuhair Ballas; Mark Ballow; R Michael Blaese; Francisco A Bonilla; Mary Ellen Conley; Charlotte Cunningham-Rundles; Alexandra H Filipovich; Ramsay Fuleihan; Erwin W Gelfand; Vivian Hernandez-Trujillo; Steven M Holland; Richard Hong; Howard M Lederman; Harry L Malech; Stephen Miles; Luigi D Notarangelo; Hans D Ochs; Jordan S Orange; Jennifer M Puck; John M Routes; E Richard Stiehm; Kathleen Sullivan; Troy Torgerson; Jerry Winkelstein
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

6.  Intrathecal synthesis of virus-specific oligoclonal antibodies in patients with enterovirus infection of the central nervous system.

Authors:  R Kaiser; R Dörries; R Martin; U Fuhrmeister; K F Leonhardt; V ter Meulen
Journal:  J Neurol       Date:  1989-10       Impact factor: 4.849

7.  Paralytic poliomyelitis in a child with agammaglobulinemia.

Authors:  W Abo; S Chiba; T Yamanaka; T Nakao; M Hara; I Tagaya
Journal:  Eur J Pediatr       Date:  1979-09       Impact factor: 3.183

8.  Characterization of genetic changes occurring in attenuated poliovirus 2 during persistent infection in mouse central nervous systems.

Authors:  E J Rozhon; A K Wilson; B Jubelt
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

Review 9.  Diabetes mellitus due to viruses--some recent developments.

Authors:  T M Szopa; P A Titchener; N D Portwood; K W Taylor
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

10.  Use of a human plaque-forming cell assay to study peripheral blood bursa-equivalent cell activation and excessive suppressor cell activity in humoral immunodeficiency.

Authors:  H G Herrod; R H Buckley
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.